These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20629183)

  • 1. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent.
    Subramanian S; Yajnik V; Sands BE; Cullen G; Korzenik JR
    Inflamm Bowel Dis; 2011 Jan; 17(1):99-104. PubMed ID: 20629183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.
    Beigel F; Schnitzler F; Paul Laubender R; Pfennig S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Inflamm Bowel Dis; 2011 Jan; 17(1):91-8. PubMed ID: 20564536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced lupus due to anti-tumor necrosis factor alpha agents.
    Costa MF; Said NR; Zimmermann B
    Semin Arthritis Rheum; 2008 Jun; 37(6):381-7. PubMed ID: 17977585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
    Verma HD; Scherl EJ; Jacob VE; Bosworth BP
    J Dig Dis; 2011 Oct; 12(5):379-83. PubMed ID: 21955431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced lupus erythematosus presenting with cardiac tamponade: a case report and literature review.
    Harnett DT; Chandra-Sekhar HB; Hamilton SF
    Can J Cardiol; 2014 Feb; 30(2):247.e11-2. PubMed ID: 24373757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies in psoriatic patients treated with anti-TNF-α therapy.
    Bardazzi F; Odorici G; Virdi A; Antonucci VA; Tengattini V; Patrizi A; Balestri R
    J Dtsch Dermatol Ges; 2014 May; 12(5):401-6. PubMed ID: 24797746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced lupus erythematosus.
    Vedove CD; Del Giglio M; Schena D; Girolomoni G
    Arch Dermatol Res; 2009 Jan; 301(1):99-105. PubMed ID: 18797892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature.
    Shovman O; Tamar S; Amital H; Watad A; Shoenfeld Y
    Clin Rheumatol; 2018 Feb; 37(2):563-568. PubMed ID: 29063464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients.
    Matsumura R; Umemiya K; Sugiyama T; Sueishi M; Umibe T; Ichikawa K; Yoshimura M;
    Clin Exp Rheumatol; 2009; 27(3):416-21. PubMed ID: 19604433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.
    Vermeire S; Noman M; Van Assche G; Baert F; Van Steen K; Esters N; Joossens S; Bossuyt X; Rutgeerts P
    Gastroenterology; 2003 Jul; 125(1):32-9. PubMed ID: 12851868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
    van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
    Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
    [No Abstract]   [Full Text] [Related]  

  • 14. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study.
    Pink AE; Fonia A; Allen MH; Smith CH; Barker JN
    Br J Dermatol; 2010 Apr; 162(4):780-5. PubMed ID: 19863499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
    Cavazzana I; Bobbio-Pallavicini F; Franceschini F; Bazzani C; Ceribelli A; Bravi E; Zingarelli S; Caporali R; Cattaneo R; Montecucco CM
    Clin Exp Rheumatol; 2007; 25(5):676-83. PubMed ID: 18078613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease--what is the role of anti-TNF antibody?
    Farkas K; Nagy F; Kovács L; Wittmann T; Molnár T
    J Crohns Colitis; 2013 May; 7(4):e143-5. PubMed ID: 22818164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-alpha antagonist induced lupus on three different agents.
    Mudduluru BM; Shah S; Shamah S; Swaminath A
    Postgrad Med; 2017 Mar; 129(2):304-306. PubMed ID: 27748629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic.
    Wetter DA; Davis MD
    Mayo Clin Proc; 2009 Nov; 84(11):979-84. PubMed ID: 19880688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.